Fosamprenavir

Abstract

Various toxicities: 7 case reports In an observational single-arm retrospective study involving 137 patients with human immunodeficiency virus-I (HIV-I) receiving treatment at a hospital in Italy with combination antiretroviral regimens that included fosamprenavir, 7 patients [ages and sexes not stated] were described who exhibited an elevation in AST, ALT, glucose, cholesterol or triglycerides or its worsening during treatment with fosamprenavir [routes, dosages and durations of treatments to reactions onsets not stated]. All the patients with HIV-I infection, started receiving combination antiretroviral regimens that included fosamprenavir. The patients were scheduled to be followed-up for a minimum of 24 weeks and a maximum of 48 weeks. However, all the patients developed fosamprenavir therapy-related adverse events, which included: worsening of previously elevated AST and ALT along with elevation of triglycerides (1 patient), worsening of previously elevated glucose level along with elevation of cholesterol and triglycerides (1 patient), elevation of AST and ALT along with worsening of previously elevated cholesterol and triglycerides (1 patient), worsening of previously elevated glucose (1 patient), worsening of previously elevated AST, ALT and cholesterol (1 patient), worsening of previously elevated AST and ALT (1 patient), and worsening of previously elevated ALT, AST and elevation of cholesterol (1 patient). Despite the aforementioned toxicities, fosamprenavir was continued in all the patients.